» Articles » PMID: 34958429

A Multidisciplinary Perspective on the Complex Interactions Between Sleep, Circadian, and Metabolic Disruption in Cancer Patients

Overview
Specialty Oncology
Date 2021 Dec 27
PMID 34958429
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Sleep is a basic need that is frequently set aside in modern societies. This leads to profound but complex physiological maladaptations in the body commonly referred to as circadian disruption, which recently has been characterized as a carcinogenic factor and reason for poor treatment outcomes, shortened survival, and reduced quality of life in cancer patients. As sleep and circadian physiology in cancer patients spans several disciplines including nursing science, neurology, oncology, molecular biology and medical technology, there is a lack of comprehensive and integrated approaches to deal with this serious and growing issue and at best a fractionated understanding of only part of the problem among researchers within each of these segments. Here, we take a multidisciplinary approach to comprehensively review the diagnosis and impact of sleep and circadian disruption in cancer patients. We discuss recent discoveries on molecular regulation of the circadian clock in healthy and malignant cells, the neurological and endocrine pathways controlling sleep and circadian rhythmicity, and their inputs to and outputs from the organism. The benefits and drawbacks of the various technologies, devices, and instruments used to assess sleep and circadian function, as well as the known consequences of sleep disruption and how sleep can be corrected in cancer patients, will be analyzed. We will throughout the review highlight the extensive crosstalk between sleep, circadian rhythms, and metabolic pathways involved in malignancy and identify current knowledge gaps and barriers for addressing the issue of sleep and circadian disruption in cancer patients. By addressing these issues, we hope to provide a foundation for further research as well as better and more effective care for the patients in the future.

Citing Articles

Exploring the impact of chronotype, chrononutrition and lifestyle on bladder cancer.

Strojny Z, Kawka E, Strojny M, Kucz-Chrostowska A, Zuraszek-Szymanska J, Sikora W Int Urol Nephrol. 2025; .

PMID: 39982656 DOI: 10.1007/s11255-025-04371-y.


Circadian rhythms and cancer: implications for timing in therapy.

El-Tanani M, Rabbani S, Ali A, Alfaouri I, Al Nsairat H, Al-Ani I Discov Oncol. 2024; 15(1):767.

PMID: 39692981 PMC: 11655929. DOI: 10.1007/s12672-024-01643-4.


Impact of Lifestyle Interventions on Gynecologic Cancers: Beyond Diet and Exercise.

McKenzie N, Ahmad S Am J Lifestyle Med. 2024; 18(1):7-20.

PMID: 39184272 PMC: 11339763. DOI: 10.1177/15598276221123764.


The Potential of Integrative Cancer Treatment Using Melatonin and the Challenge of Heterogeneity in Population-Based Studies: A Case Report of Colon Cancer and a Literature Review.

Smorodin E, Chuzmarov V, Veidebaum T Curr Oncol. 2024; 31(4):1994-2023.

PMID: 38668052 PMC: 11049198. DOI: 10.3390/curroncol31040149.


The Impact of Immunotherapy on Sleep and Circadian Rhythms in Patients with Cancer.

Balachandran D, Bashoura L, Sheshadri A, Manzullo E, Faiz S Front Oncol. 2023; 13:1295267.

PMID: 38090501 PMC: 10711041. DOI: 10.3389/fonc.2023.1295267.


References
1.
Laing E, Moller-Levet C, Poh N, Santhi N, Archer S, Dijk D . Blood transcriptome based biomarkers for human circadian phase. Elife. 2017; 6. PMC: 5318160. DOI: 10.7554/eLife.20214. View

2.
Roscoe J, Perlis M, Pigeon W, ONeill K, Heckler C, Matteson-Rusby S . Few changes observed in polysomnographic-assessed sleep before and after completion of chemotherapy. J Psychosom Res. 2011; 71(6):423-8. PMC: 4157519. DOI: 10.1016/j.jpsychores.2011.08.003. View

3.
Dimova E, Jakupovic M, Kubaichuk K, Mennerich D, Chi T, Tamanini F . The Circadian Clock Protein CRY1 Is a Negative Regulator of HIF-1α. iScience. 2019; 13:284-304. PMC: 6416729. DOI: 10.1016/j.isci.2019.02.027. View

4.
Dallmann R, Brown S, Gachon F . Chronopharmacology: new insights and therapeutic implications. Annu Rev Pharmacol Toxicol. 2013; 54:339-61. PMC: 3885389. DOI: 10.1146/annurev-pharmtox-011613-135923. View

5.
Latorre D, Kallweit U, Armentani E, Foglierini M, Mele F, Cassotta A . T cells in patients with narcolepsy target self-antigens of hypocretin neurons. Nature. 2018; 562(7725):63-68. DOI: 10.1038/s41586-018-0540-1. View